Publication:
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome

dc.contributor.authorHarald Noedlen_US
dc.contributor.authorSrivicha Krudsooden_US
dc.contributor.authorWattana Leowattanaen_US
dc.contributor.authorNoppadon Tangpukdeeen_US
dc.contributor.authorWipa Thanachartweten_US
dc.contributor.authorSornchai Looareesuwanen_US
dc.contributor.authorRobert Scott Milleren_US
dc.contributor.authorMark Fukudaen_US
dc.contributor.authorKrisada Jongsakulen_US
dc.contributor.authorKritsanai Yingyuenen_US
dc.contributor.authorSabaithip Sriwichaien_US
dc.contributor.authorColin Ohrten_US
dc.contributor.authorCharles Knirschen_US
dc.contributor.otherMedizinische Universitat Wienen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherWalter Reed Army Institute of Researchen_US
dc.contributor.otherPfizer Inc.en_US
dc.date.accessioned2018-08-24T02:10:57Z
dc.date.available2018-08-24T02:10:57Z
dc.date.issued2007-02-01en_US
dc.description.abstractAzithromycin when used in combination with faster-acting antimalarials has proven efficacious in treating Plasmodium falciparum malaria in phase 2 clinical trials. The aim of this study was to establish optimal combination ratios for azithromycin in combination with either dihydroartemisinin or quinine, to determine the clinical correlates of in vitro drug sensitivity for these compounds, and to assess the cross-sensitivity patterns. Seventy-three fresh P. falciparum isolates originating from patients from the western border regions of Thailand were successfully tested for their drug susceptibility in a histidine-rich protein 2 (HRP2) assay. With overall mean fractional inhibitory concentrations of 0.84 (95% confidence interval [CI] = 0.77 to 1.08) and 0.78 (95% CI = 0.72 to 0.98), the interactions between azithromycin and dihydroartemisinin, as well as quinine, were classified as additive, with a tendency toward synergism. The strongest tendency toward synergy was seen with a combination ratio of 1:547 for the combination with dihydroartemisinin and 1:44 with quinine. The geometric mean 50% inhibitory concentration (IC50) of azithromycin was 2,570.3 (95% CI = 2,175.58 to 3,036.58) ng/ml. The IC50s for mefloquine, quinine, and chloroquine were 11.42, 64.4, and 54.4 ng/ml, respectively, suggesting a relatively high level of background resistance in this patient population. Distinct correlations (R = 0.53; P = 0.001) between quinine in vitro results and parasite clearance may indicate a compromised sensitivity to this drug. The correlation with dihydroartemisinin data was weaker (R = 0.34; P = 0.038), and no such correlation was observed for azithromycin. Our in vitro data confirm that azithromycin in combination with artemisinin derivatives or quinine exerts additive to synergistic interactions, shows no cross-sensitivity with traditional antimalarials, and has substantial antimalarial activity on its own. Copyright © 2007, American Society for Microbiology. All Rights Reserved.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.51, No.2 (2007), 651-656en_US
dc.identifier.doi10.1128/AAC.01023-06en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-33846597493en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/25017
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33846597493&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleIn vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcomeen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33846597493&origin=inwarden_US

Files

Collections